

Enhancing Substance Abuse Treatment Services to Address Hepatitis Infection Among Intravenous Drug Users Hepatitis Test and Vaccine Tracking Form

SUPPORTING STATEMENT

B. Collections of Information Employing Statistical Methods

1. Respondent Universe and Sampling Methods

To minimize response burden, SAMHSA will allow the designated Opioid Treatment Programs to self-select. The designated sites are in States that have a high prevalence of HIV/AIDS infection as defined in the Minority AIDS Initiative (MAI). The OTPs reside in California, New Mexico, New York, Ohio, Hawaii, Minnesota, Connecticut, Massachusetts, and Pennsylvania. (States Identified with High OTP Substance Abuse associated Morbidity)

Table 1: Providers within the 13 MAI States.

| State | OTPs | Total Providers |
|---------------|------|-----------------|
| Ohio | 2 | 2 |
| New Mexico | 1 | 1 |
| California | 2 | 2 |
| New York | 2 | 2 |
| Hawaii | 1 | 1 |
| Minnesota | 1 | 1 |
| Connecticut | 1 | 1 |
| Massachusetts | 1 | 1 |
| Pennsylvania | 1 | 1 |
| Total | 12 | 12 |

Sample Size: 264 Test Kits and 10, 628 Vaccines

2. Information Collection Procedures

When a client comes into the provider organization to request to be screened for hepatitis; the provider will select a no cost hepatitis test along with the corresponding Hepatitis Test and Vaccine Tracking Form. The provider will complete the form at the time the test is performed. After the completion of the form, it is placed in the client's record. At the time the provider receives the results, a decision is made to continue with the vaccination series or refer the patient to follow-up services. Approximately one month after the initial intake, the forms are sent to the contractor.

3. Methods to Maximize Response Rates

SAMHSA/CSAT anticipates that they will receive near 80 percent response rate because the form would be completed whenever a no cost test kit or vaccine is administered by the provider. The test kits and vaccines will have a unique number as well as a lot number.

4. **Test of Procedures**

This form has been revised by removing all direct identifying variables that may represent possible risk of patient disclosure.

5. **Statistical Consultants**

This material has been reviewed by:

| | | |
|-----------------------|--------------------------|--------------|
| Randolph Edmead, M.S. | Project Coordinator | 301-589-4020 |
| | DB Consulting Group, Inc | |

| | | |
|------------------------|----------------------------|--------------|
| Anthony Campbell, D.O. | Government Project Officer | 240-276-2702 |
| | SAMHSA/CSAT | |

List of Attachments

Attachment A: SAMHSA/CSAT Hepatitis Tracking Form